NEW YORK (GenomeWeb) – Epic Sciences and Genomic Health said today that Medicare contractor Palmetto GBA has issued a draft local coverage determination (LCD) for the Oncotype DX AR-V7 Nucleus Detect test.
The companies said that if finalized, the LCD would extend coverage of the test to 25,000 Medicare patients with advanced prostate cancer.